• Oncoceutics COO Lee Schalop gets ready to ride in support of the the Brain Power team led by Andrew Lassman, MD, principal investigator of the company’s “ONC201 in Adults With Recurrent H3 K27M-mutant Glioma” study as part of 2019 Velocity, Columbia’s Ride to End Cancer.

Photostream